

FOR IMMEDIATE RELEASE
PRESS RELEASE
Tuesday, October 25, 2006

**ANGIOTECH PHARMACEUTICALS FILES PRELIMINARY
SHORT FORM PROSPECTUS AND REGISTRATION
STATEMENT**

VANCOUVER, BC, October 25, 2006 – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) today filed a Form 6-K (the “Form 6-K”) with the U.S. Securities and Exchange Commission (“SEC”), which contains its financial statements for the years ended December 31, 2005 and 2004 and the fifteen months ended December 31, 2003 and as of December 31, 2005 and 2004, and its financial statements for the six months ended June 30, 2006 and 2005 (together, the “Angiotech Statements”). The Form 6-K was filed in conjunction with Angiotech’s filing today of a preliminary short form prospectus (the “Preliminary Prospectus”) with the British Columbia Securities Commission and a Registration Statement (the “Registration Statement”) with the SEC to register the exchange of its previously issued 7.75% Senior Subordinated Notes due April 1, 2014 for new 7.75% Senior Subordinated Notes due April 1, 2014. The notes to be issued to holders that accept the exchange offer are identical to the previously issued notes in all material respects, except that the new notes will be registered under the U.S. Securities Act of 1933.

The Angiotech Statements included in the Form 6-K have been supplemented to include a new audited note required in connection with the Preliminary Prospectus and Registration Statement. The new note provides condensed consolidated financial information for Angiotech and its subsidiaries that have guaranteed the notes. Other than the addition of this new footnote, no changes have been made to the balance sheets, statements of income, statements of stockholder’s equity or statements of cash flow contained in the Angiotech Statements or to the note disclosure previously accompanying the Angiotech Statements.

The Form 6-K also includes the financial statements of American Medical Instruments Holdings Inc. (“AMI”), a company acquired by Angiotech on March 23, 2006, for the three years ended December 31, 2005 (the “AMI Statements”). The pre-acquisition AMI Statements have been restated to reflect the correction of errors in the previously filed Statements on Form 6-K on June 6, 2006 and include information required to comply with SEC reporting requirements. The AMI Statements included in the Form 6-K for the years ended December 31, 2005, 2004 and 2003 have been restated to correct errors related to (i) accounting for the AMI asset values recorded in connection with the 2003 acquisition of 65% of AMI by one of the parties from whom Angiotech acquired AMI, (ii) accounting for certain warrants issued by AMI as a liability instead of equity, (iii) accounting for changes in debt instruments in 2004 as a modification and not an extinguishment of debt, and (iv) other less significant items. The restatement of the AMI Statements also require Angiotech to update and refile its pro forma statements (the “Pro

Forma Statements”) relating to the AMI acquisition that were previously filed by Angiotech on Form 6-K on June 6, 2006. The updated Pro Forma Statements also reflect a revision in Angiotech’s purchase price allocation for AMI and updates to assumptions used in the preparation and initial filing of the Pro Forma Statements.

The Form 6-K also includes financial statements of Quill Medical, Inc. for the years ended, and as of, December 31, 2004 and 2005 and for the quarter ended March 31, 2006 (the “Quill Statements”) that are required by SEC regulations to be included in the Registration Statement.

In connection with the foregoing, Angiotech has also filed the Form 6-K with Canadian securities regulators on SEDAR in its entirety as well as an amended business acquisition report reflecting the AMI Statements, the Angiotech Statements, the Pro Forma Statements and the Quill Statements. Further information regarding, and copies of, the Angiotech Statements, the AMI Statements, the Pro Forma Statements, and the Quill Statements are available at www.SEDAR.com. The Form 6-K released today is available at www.sec.gov/edgar.shtml

The Registration Statement relating to the exchange offer has been filed with the SEC but has not yet become effective. The notes to be issued in connection with the exchange offer may not be offered nor may offers to exchange be accepted prior to the time the Registration Statement becomes effective.

FOR ADDITIONAL INFORMATION:

Analysts and Institutional Investors:

Janet Craig
VP, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
janet@angio.com

Media and Retail Investors:

Jodi Regts
Manager, Corporate Communications
Angiotech Pharmaceuticals, Inc.
jregts@angio.com
(604) 221-7930

-END-